Mersana Therapeutics (MRSN) Prices 8M Share Common Offering at $19/Sh

Mersana Therapeutics (MRNS) to Offer 5M Shares

May 28, 2020 6:03 AM EDT

Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of 5 million shares of its common stock. All shares being offered are to be sold by Mersana. As part of the offering, Mersana intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock... More

Mersana (MRSN) PT Raised to $19 at Wedbush

May 27, 2020 12:42 PM EDT

Wedbush analyst David Nierengarten raised the price target on Mersana (NASDAQ: MRSN) to $19.00 (from $12.00) while maintaining an Outperform rating.

XMT-1536 Expansion Impresses: Broad, Deep and Deepening Responses in PROC... More

Pre-Open Stock Movers 05/27: (HTZ) (PHUN) (MRSN) (STNE) (CPIX) (HTBX) (SAVE) (more...)

May 27, 2020 8:44 AM EDT

Today's Pre-Open Stock Movers:

Hertz Global Holdings, Inc. (NYSE: HTZ) +58%; announced over the weekend it and certain of its U.S. and Canadian subsidiaries have filed voluntary petitions for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Phunware (NASDAQ: PHUN) +38%; announced today its strategic relationship with American Made Media Consultants on the development, launch and ongoing management and evolution of the Trump-Pence... More

Mersana Therapeutics (MRSN) Announces Positive Interim Data from Expansion Portion of the XMT-1536 Phase 1 Study

May 27, 2020 6:10 AM EDT

Mersana Therapeutics, Inc. (NASDAQ: MRSN) today reported interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma. The Company will host a conference call and webcast today, Wednesday, May 27, 2020, at 8:00 a.m. ET during which investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute and members of the... More